GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Coherus Biosciences
Coherus is a biopharmaceutical company focused on biosimilars and oncology. Its stock price is a story of its transition from selling blockbuster knockoffs to developing its own innovative drugs. The chart reflects its success in commercialization and clinical trials.
Share prices of companies in the market segment - General oncology therapy
Coherus BioSciences develops and commercializes biosimilars (analogs of expensive biologics) and its own immuno-oncology drugs. We classify it as "General Oncology Therapy" as this is its key growth vector. The graph below shows the dynamics of this sector, where both innovation and access to treatment are important.
Broad Market Index - GURU.Markets
Coherus BioSciences is a biopharmaceutical company that commercializes biosimilars and develops its own oncology drugs. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
CHRS - Daily change in the company's share price Coherus Biosciences
Change_co for Coherus, a biopharmaceutical company, measures its volatility. It reflects its sensitivity to competition in the biosimilar market and the success of its oncology drugs. This metric is important for pharmaceutical sector analysis on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - General oncology therapy
Coherus BioSciences, Inc. is a biotech company. This chart highlights the sector's high volatility. Comparing it to the CHRS, which focuses on biosimilars and oncology, helps assess how diversification impacts its risks.
Daily change in the price of a broad market stock, index - GURU.Markets
Coherus Biosciences specializes in biosimilars—more affordable alternatives to expensive biotech drugs. The company's success depends on its ability to compete with pharmaceutical giants. This competitive dynamic creates volatility, which is part of the overall picture of the healthcare sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Coherus Biosciences
Coherus BioSciences' year-over-year performance is a story of the transition from biosimilars to innovative oncology drugs. Its market capitalization change over the past 12 months reflects not only the sales of its blockbuster analogs but also the success of commercializing its own immuno-oncology drug, which represents a fundamental shift in its business model.
Annual dynamics of market capitalization of the market segment - General oncology therapy
Coherus BioSciences, Inc. is a biopharmaceutical company focused on the commercialization of biosimilars and the development of immuno-oncology drugs. The chart illustrates how its hybrid strategy, combining a stable biosimilar business with risky R&D, impacts its performance.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Coherus, with its portfolio of biosimilars and new oncology drugs, is a complex story. Its stock price reflects not so much general cycles as its success in competing with pharma giants and progress in its own developments. The chart is a bet on the company's successful transformation from a copycat to an innovator.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Coherus Biosciences
Coherus Biosciences specializes in biosimilars and oncology. Its price dynamics are directly dependent on news: successful clinical trials, FDA approvals, or the launch of a new drug can trigger a sharp rise within a month. Conversely, regulatory delays immediately impact its market capitalization, as this chart demonstrates.
Monthly dynamics of market capitalization of the market segment - General oncology therapy
This chart reflects the dynamics of the biotech sector, particularly oncology. For Coherus, with its diversified portfolio, it serves as a backdrop. Its movements demonstrate how competition in the biosimilar market and advances in proprietary drug development are impacting the entire industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Coherus Biosciences is a biopharmaceutical company focused on the commercialization of biosimilars and the development of its own oncology drugs. It operates on a hybrid model. The full market chart allows investors to assess how they weigh the stability of biosimilar sales against the risks and potential of Coherus's own developments.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Coherus Biosciences
Coherus BioSciences is a biopharmaceutical company focused on biosimilars and immuno-oncology. Its weekly stock price is driven by news of the approval and launch of new biosimilars, as well as the results of clinical trials of its own oncology drugs.
Weekly dynamics of market capitalization of the market segment - General oncology therapy
Coherus Biosciences specializes in biosimilars—low-cost alternatives to expensive biotech drugs. Its success depends on its ability to win patent disputes and capture market share from originators. The chart below shows how news about court rulings and new product launches impacts its stock price.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Coherus specializes in biosimilars. Its success depends on patent disputes and competition, not the state of the economy. The chart shows how the company's shares are operating independently, ignoring general market trends and moving based on internal news.
Market capitalization of the company, segment and market as a whole
CHRS - Market capitalization of the company Coherus Biosciences
Coherus Biosciences' market capitalization dynamics reflect its transformation from a biosimilar-focused company into a full-fledged oncology company. Its chart shows how investors view its ability not only to replicate existing drugs but also to develop and commercialize its own innovative therapies.
CHRS - Share of the company's market capitalization Coherus Biosciences within the market segment - General oncology therapy
Coherus Biosciences is a biopharmaceutical company focused on the development and commercialization of biosimilars (analogs of expensive biologics) and its own oncology drugs. Its market share is growing. The chart demonstrates the success of its hybrid strategy, combining stable revenue from biosimilars with the potential for innovation.
Market capitalization of the market segment - General oncology therapy
Here's a chart showing the biotech sector's market capitalization. Coherus Biosciences is a leader in the biosimilar market, also developing its own innovative drugs. Its market performance exemplifies a hybrid strategy: stable revenue from similar products is used to fund risky but potentially breakthrough developments.
Market capitalization of all companies included in a broad market index - GURU.Markets
Coherus Biosciences specializes in the development and commercialization of biosimilars and original oncology drugs. Its market capitalization reflects its hybrid business model. The chart below shows the economic weight of companies operating at the intersection of generics and innovation.
Book value capitalization of the company, segment and market as a whole
CHRS - Book value capitalization of the company Coherus Biosciences
Coherus's book value is derived from its production capacity and intellectual property in its portfolio of biosimilars and its own oncology drugs. This chart tells the story of a company that builds its business on two pillars: competing with blockbusters through biosimilars and developing its own innovative drugs.
CHRS - Share of the company's book capitalization Coherus Biosciences within the market segment - General oncology therapy
Coherus Biosciences focuses on biosimilars and oncology. The chart shows its share of real assets. These include its R&D centers and, more importantly, the commercial infrastructure that allows it to successfully launch more affordable versions of expensive biologics.
Market segment balance sheet capitalization - General oncology therapy
Coherus Biosciences, a biopharmaceutical company with its own manufacturing facility, is more capital-intensive than R&D startups. The chart below illustrates the scale of the entire pharmaceutical sector, providing context for assessing its integrated model.
Book value of all companies included in the broad market index - GURU.Markets
Coherus Biosciences focuses on biosimilars and the development of proprietary oncology drugs. The company's assets include its manufacturing and R&D capabilities. Its stake in BCap_All provides its physical scale in creating more affordable versions of expensive drugs and developing new ones.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Coherus Biosciences
Coherus Biosciences is a biopharmaceutical company. Its valuation is below book value, reflecting the intense competition in the biosimilar market and investor concerns about its ability to bring new, successful products to market.
Market to book capitalization ratio in a market segment - General oncology therapy
Coherus BioSciences develops and markets biosimilar and original oncology drugs. This metric reflects how the market evaluates its product portfolio and its ability to compete with large pharmaceutical companies, weighing sales revenue against research costs.
Market to book capitalization ratio for the market as a whole
Coherus Biosciences specializes in biosimilars (analogs of expensive biotech drugs) and its own oncology drugs. It operates under a hybrid model. This chart helps understand how the market values a company that combines a stable biosimilar business with risky but potentially breakthrough developments.
Debts of the company, segment and market as a whole
CHRS - Company debts Coherus Biosciences
Coherus Biosciences, a biopharmaceutical company focused on biosimilars and oncology, uses a debt strategy to finance its commercial and clinical efforts. Capital is needed to bring cheaper analogs of expensive biologics to market and to develop its own innovative drugs, which requires significant investment.
Market segment debts - General oncology therapy
Coherus Biosciences specializes in the development and commercialization of biosimilars—more affordable alternatives to expensive biologic drugs. This business requires investment in clinical trials to prove equivalence. This chart shows how the company funds its research and development efforts in an effort to reduce treatment costs for patients.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Coherus Biosciences
Coherus Biosciences focuses on biosimilars and the development of proprietary oncology drugs. Bringing biosimilars to market requires lower, but still significant, costs compared to original drugs. This chart shows how the company finances its projects, allowing one to assess its financial strategy and risks in the competitive pharmaceutical market.
Market segment debt to market segment book capitalization - General oncology therapy
Coherus Biosciences focuses on the development and commercialization of biosimilars and innovative immuno-oncology therapeutics. The chart shows debt trends in their sector. It helps assess how the company balances its stable biosimilar business with risky but potentially high-return oncology developments, and how this impacts its debt.
Debt to book value of all companies in the market
Coherus Biosciences develops and commercializes biosimilars and innovative oncology drugs. The shift from R&D to sales changes the financial model: the company begins generating revenue but may also incur debt for marketing. This chart helps assess Coherus's current stage. Does it leverage debt for commercialization, following overall market trends?
P/E of the company, segment and market as a whole
P/E - Coherus Biosciences
Coherus Biosciences develops and commercializes biosimilars and innovative oncology drugs. This chart shows how the market evaluates its hybrid business model. This evaluation depends on both the success of its lower-cost generic versions of brand-name drugs and the potential of its own developments.
P/E of the market segment - General oncology therapy
This chart of biopharmaceutical companies serves as a benchmark for Coherus Biosciences. It reflects how investors value the sector on average. Comparison with it helps understand how the market views Coherus's strategy, which focuses on biosimilars (analogs of expensive biologics), which are less risky but also lower-margin than developing innovative drugs.
P/E of the market as a whole
Coherus Biosciences focuses on the development and commercialization of biosimilars (copies of complex biological drugs) and its own oncology drugs. It's a hybrid strategy. This chart of general pharmaceutical industry sentiment helps us understand what investors value more: the predictable biosimilars business or the risky but potentially more profitable innovative drugs business.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Coherus Biosciences
Coherus BioSciences is a biopharmaceutical company focused on the development and commercialization of biosimilars and original oncology drugs. This graph reflects expectations for its hybrid business model. The valuation depends on sales volumes of biosimilars, which compete with expensive biologics, and the success of its own immuno-oncology developments.
%20P%2FE%20Coherus%20Biosciences&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Coherus-Biosciences&v=1772634889110 "Chart of the company's future (projected) P/E Coherus Biosciences")
Future (projected) P/E of the market segment - General oncology therapy
Coherus BioSciences develops and commercializes biosimilars, which are more affordable versions of expensive biologic drugs. This chart reflects investor expectations for the company's profitability relative to the sector. It allows one to assess the market's perception of its ability to compete with original-brand drugs and capture market share.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-General-oncology-therapy&v=1772634889122 "Future (projected) P/E graph of the market segment - General oncology therapy")
Future (projected) P/E of the market as a whole
Coherus Biosciences is a biopharmaceutical company focused on the development and commercialization of biosimilars (analogs of biological drugs) and innovative oncology drugs. This overall market sentiment graph is important for CHRS, but their business is driven by specific factors: the success of biosimilar launches and clinical trial results.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772634889127 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Coherus Biosciences
Coherus BioSciences is a biopharmaceutical company focused on the development and commercialization of biosimilars (analogs of biological drugs) and original immuno-oncology therapies. This chart shows the financial results of a hybrid strategy that combines the stability of biosimilars with the potential for innovation.
Profit of companies in the market segment - General oncology therapy
Coherus BioSciences specializes in the development and commercialization of biosimilars—analogs of expensive biological drugs. This chart shows profitability in the oncology sector. For CHRS, this reflects the trend toward lower healthcare costs. Their biosimilars offer more affordable alternatives for treating cancer and other diseases.
Overall market profit
Coherus Biosciences is a biopharmaceutical company focused on the development and commercialization of biosimilars (analogs of biological drugs) and its own oncology drugs. Biosimilars make treatment more accessible. The company's growth depends on the successful launch of its products. This graph does not reflect the specifics of competition in the pharmaceutical market.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Coherus Biosciences
Coherus Biosciences focuses on the development and commercialization of biosimilars (analogs of complex biological drugs) and its own innovative oncology drugs. The revenue forecast presented here is dependent on the successful launch of its biosimilars and the progress of its immuno-oncology candidates in clinical trials.
%20profit%20of%20the%20company%20Coherus%20Biosciences&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Coherus-Biosciences&v=1772634889194 "Graph of future (projected) profit of the company Coherus Biosciences")
Future (predicted) profit of companies in the market segment - General oncology therapy
Coherus Biosciences focuses on biosimilars (analogs of expensive biological drugs) and is developing its own portfolio of oncology drugs. The profit forecast for this sector depends on its success in competing with original drugs. This chart reflects analysts' expectations for the growth of the biosimilar market, which helps reduce healthcare costs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-General-oncology-therapy&v=1772634889219 "Graph of future (predicted) profits of companies in a market segment - General oncology therapy")
Future (predicted) profit of the market as a whole
Coherus BioSciences specializes in the development and commercialization of biosimilars and innovative oncology drugs. Its success depends on competition and regulatory approvals. The profit projections shown here impact healthcare budgets, which drive demand for lower-cost biosimilars.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772634889268 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Coherus Biosciences
Coherus Biosciences specializes in the development and commercialization of biosimilars (analogs of complex biological drugs) and its own oncology drugs. This chart shows how investors value its combined revenue. This valuation depends on the success of biosimilar launches and progress in developing innovative drugs.
P/S market segment - General oncology therapy
Coherus Biosciences focuses on the development and commercialization of biosimilars—analogs of expensive biologic drugs—making treatment more accessible. The company also develops original oncology drugs. This chart reflects the average revenue estimate for the sector, helping to understand how the market views Coherus's hybrid business model.
P/S of the market as a whole
Coherus BioSciences is a biopharmaceutical company focused on the development and commercialization of biosimilars (copies of complex biological drugs) and innovative oncology therapies. Its revenue depends on the successful launch of its products. This chart provides a general market backdrop for assessing investor sentiment regarding revenue prospects in the biosimilars sector.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Coherus Biosciences
Coherus BioSciences develops and commercializes biosimilars—more affordable versions of expensive biologic drugs. This chart shows how investors assess the company's future sales. It reflects its ability to successfully market similar versions of blockbuster drugs and compete with originators.
%20P%2FS%20Coherus%20Biosciences&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Coherus-Biosciences&v=1772634889485 "The graph of the company's future (projected) P/S Coherus Biosciences")
Future (projected) P/S of the market segment - General oncology therapy
Coherus BioSciences focuses on the development and commercialization of biosimilars and innovative oncology drugs. This chart shows how the market views its dual strategy, combining the more predictable biosimilar business with high-risk but potentially profitable innovations.
%20P%2FS%20market%20segment%20graph%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-General-oncology-therapy&v=1772634889520 "Future (projected) P/S market segment graph - General oncology therapy")
Future (projected) P/S of the market as a whole
Coherus Biosciences specializes in the development and commercialization of biosimilars—more affordable alternatives to expensive biologic drugs. Their success depends on regulatory approvals and competition. This graph, reflecting the state of the healthcare system, is important. A stable economy supports efforts to reduce drug costs, which creates demand for their products.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772634889531 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Coherus Biosciences
Coherus Biosciences is a biopharmaceutical company that has successfully launched several biosimilars (analogs of expensive biologics) and is developing its own oncology drugs. This chart shows the revenue from sales of its commercial products. Revenue growth reflects its ability to compete with brand-name drugs and capture market share.
Sales of companies in the market segment - General oncology therapy
Coherus BioSciences is a commercial biopharmaceutical company. Their business consists of two parts: selling biosimilars (low-cost versions of expensive biologics) to increase access to treatment and developing their own innovative oncology drugs. This chart shows the contribution of revenue from sales of their various commercial products.
Overall market sales
Coherus Biosciences is a biopharmaceutical company focused on the development and commercialization of biosimilars (analogs of expensive biological drugs) and innovative oncology therapeutics. This total revenue chart includes the healthcare sector, where CHRS contributes to improving access to treatment and offering new therapeutic options.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Coherus Biosciences
Coherus Biosciences specializes in the development and commercialization of biosimilars—analogs of expensive biological drugs. This chart shows analysts' expectations for the sales of its biosimilars, which are gaining market share from original drugs after patents expire.
%20sales%20of%20the%20company%20Coherus%20Biosciences&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Coherus-Biosciences&v=1772634889958 "Schedule of future (projected) sales of the company Coherus Biosciences")
Future (projected) sales of companies in the market segment - General oncology therapy
Coherus Biosciences specializes in the development and commercialization of biosimilars—more affordable alternatives to expensive biologic drugs. This chart shows forecasts for the entire biosimilar market. This market's growth is driven by patent expirations on blockbuster drugs and healthcare systems' efforts to reduce drug costs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-General-oncology-therapy&v=1772634890012 "Schedule of future (projected) sales of companies in the market segment - General oncology therapy")
Future (projected) sales of the market as a whole
Coherus BioSciences, a company that produces biosimilars and oncology drugs, sees this chart as a reflection of healthcare trends. Rising overall economic forecasts are enabling healthcare systems to seek cost-cutting measures. Coherus' biosimilars are more affordable alternatives to expensive original drugs, creating demand for them.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772634890094 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Coherus Biosciences
Coherus BioSciences develops and commercializes biosimilars—more affordable alternatives to expensive biologic drugs. The company's profitability depends on the successful launch of these products and their ability to compete with original drugs. This chart shows how effectively Coherus is implementing its strategy to generate profit.
Market segment marginality - General oncology therapy
Coherus Biosciences specializes in the development and commercialization of biosimilars—more affordable versions of expensive biologic drugs. This indicator reflects the effectiveness of its business model. A high score indicates the successful launch of similar products and the ability to compete with original drugs.
Market marginality as a whole
Coherus Biosciences specializes in the development and commercialization of biosimilars—analogs of expensive biological drugs. The company's success depends on its ability to compete with originator brands and other biosimilar manufacturers. This overall profitability chart does not reflect the specifics of this competitive segment of the pharmaceutical market.
Employees in the company, segment and market as a whole
Number of employees in the company Coherus Biosciences
Coherus Biosciences is a biopharmaceutical company that began developing and commercializing biosimilars (analogs of expensive biological drugs) and is now expanding its business into innovative immuno-oncology. This graph shows the team working to make cancer treatment more accessible and effective.
Share of the company's employees Coherus Biosciences within the market segment - General oncology therapy
Coherus Biosciences is a biopharmaceutical company focused on the development and commercialization of biosimilars and innovative oncology drugs. Successful competition in the biosimilar market requires an effective commercial team. This chart shows its growing commercial reach and share of the total number of specialists working in this field.
Number of employees in the market segment - General oncology therapy
Coherus Biosciences specializes in the development and commercialization of biosimilars—analogs of expensive biological drugs—making treatments more accessible. This graph shows the team working to reduce the cost of cancer and autoimmune disease treatments, competing with large pharmaceutical companies.
Number of employees in the market as a whole
Coherus BioSciences, Inc. is a biopharmaceutical company specializing in the development and commercialization of biosimilars and innovative oncology therapeutics. The overall economic environment, reflected in the employment graph, influences their market. Stable employment ensures funding for the healthcare system, which facilitates the introduction of both more affordable biosimilars and new treatments.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Coherus Biosciences (CHRS)
Coherus Biosciences develops and commercializes biosimilars and original drugs. This chart reflects their hybrid model. Their capitalization per employee will be lower than that of a pure R&D biotech company, as commercialization requires significant marketing and sales network development costs.
%20of%20the%20company%20Coherus%20Biosciences%20(CHRS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Coherus-Biosciences-CHRS&v=1772634890407 "Chart of market capitalization per employee (in thousands of dollars) of the company Coherus Biosciences (CHRS)")
Market capitalization per employee (in thousands of dollars) in the market segment - General oncology therapy
Coherus BioSciences develops and commercializes biosimilars and innovative oncology drugs. The company combines R&D and commercial activities. This chart allows you to assess how the market perceives the balance between its scientific potential and commercial infrastructure per employee compared to other biopharmaceutical companies.
%20by%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-General-oncology-therapy&v=1772634890450 "Market capitalization per employee (in thousands of dollars) by market segment - General oncology therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Coherus BioSciences specializes in the development and commercialization of biosimilars (analogs of biological drugs) and innovative oncology drugs. This metric reflects its hybrid strategy, demonstrating how the company combines the more predictable biosimilar business with risky but potentially high-return developments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772634890484 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Coherus Biosciences (CHRS)
Coherus is a biosimilar company. They produce "copies" of complex biologic drugs (e.g., Lucentis, Humira). This graph illustrates their business model. R&D is needed to prove "similarity," and manufacturing is complex. This is more efficient than R&D from scratch, but more complex than generic production.
%20Chart%20Coherus%20Biosciences%20(CHRS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Coherus-Biosciences-CHRS&v=1772634890520 "Company Profit Per Employee (in thousands of dollars) Chart Coherus Biosciences (CHRS)")
Profit per employee (in thousands of dollars) in the market segment - General oncology therapy
Coherus Biosciences is a biopharmaceutical company focused on two areas: biosimilars (low-cost alternatives to expensive biologics) and the development of proprietary immuno-oncology therapies. This chart represents an industry benchmark. It reflects how effectively Coherus balances the profitable biosimilar business with high-cost R&D in innovative oncology.
%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-General-oncology-therapy&v=1772634890530 "Chart of profit per employee (in thousands of dollars) in the market segment - General oncology therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Coherus Biosciences is a biopharmaceutical company that started with biosimilars (low-cost versions of biologics) and is now developing its own innovative oncology drugs. It's a hybrid model. This chart shows the balance: stable but low-margin profits from biosimilars and high R&D costs per scientist working on new drugs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772634890546 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Coherus Biosciences (CHRS)
Coherus BioSciences focuses on the development and commercialization of biosimilars and innovative oncology drugs. This chart illustrates the hybrid biopharmaceutical model. Revenue per employee is generated both from sales of more affordable analogs of expensive drugs and from in-house development, diversifying revenue sources.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Coherus-Biosciences-CHRS&v=1772634890556 "Sales chart per company employee Coherus Biosciences (CHRS)")
Sales per employee in the market segment - General oncology therapy
Coherus Biosciences (CHRS) is a biotech company that has successfully transitioned from R&D to commercialization. They sell biosimilars and are developing their own oncology pipeline. This chart shows how effective their hybrid model (R&D + sales) is. It compares their revenue per employee to the industry average.
Sales per employee for the market as a whole
Coherus is a biotech company with a hybrid model. They produce "biosimilars" (cheap copies of expensive biologics), generating revenue and reinvesting it into developing their own innovative immuno-oncology products. This graph shows the revenue generated by their commercial and R&D teams.
Short shares by company, segment and market as a whole
Shares shorted by company Coherus Biosciences (CHRS)
Coherus (CHRS) is a biopharmaceutical company that started with biosimilars of expensive biologics and is now developing its own immuno-oncology products. This chart shows bearish bets. The rise in shorts may reflect concerns about a price war in the biosimilar market or skepticism about the success of their own oncology developments.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Coherus-Biosciences-CHRS&v=1772634890602 "Short Shares Chart for the Company Coherus Biosciences (CHRS)")
Shares shorted by market segment - General oncology therapy
Coherus (CHRS) is a biopharmaceutical company focused on biosimilars (analogs of expensive biologics) and immuno-oncology. This chart reflects the overall sentiment in the biotech sector. It shows how many investors expect price wars in the biosimilar sector or failures in new drug development.
Shares shorted by the overall market
Coherus (CHRS) produces biosimilars (generics of biotech drugs). This should be profitable during a recession. But when this chart shows panic, investors sell *all* biotech. They fear that the price war in the biosimilar sector and the risks of financing will outweigh any benefits from cost savings.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Coherus Biosciences (CHRS)
Coherus is a biotech company aggressively entering the biosimilar market (analogs of expensive drugs like Humira). It's betting on price wars in the pharmaceutical industry. This chart measures how investors assess their chances. It shows when the stock is overbought due to a successful launch or oversold due to fears of fierce competition.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Coherus-Biosciences-CHRS&v=1772634890640 "RSI 14 indicator chart for the company's stock Coherus Biosciences (CHRS)")
RSI 14 Market Segment - General oncology therapy
Coherus Biosciences is a biopharmaceutical company with a hybrid model. They develop and commercialize both biosimilars (analogs of expensive drugs) and their own innovative oncology drugs. This chart reflects the overall sentiment in the biotech sector and helps assess how the market views this speculative industry as a whole.
RSI 14 for the overall market
Coherus (CHRS) develops biosimilars (copies of expensive drugs). This chart shows that its business is betting on savings in healthcare. In times of panic and recession, healthcare systems desperately seek ways to cut costs, which accelerates the transition to Coherus's biosimilars.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CHRS (Coherus Biosciences)
Coherus (CHRS) is a biopharmaceutical company focused on biosimilars (analogs of expensive drugs) and the development of proprietary oncology drugs. This chart shows the average 12-month forecast. It reflects analysts' assessments of the company's success in launching biosimilars and the potential of its oncology pipeline.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CHRS-Coherus-Biosciences&v=1772634890715 "A chart showing analyst consensus forecasts for the expected stock price. CHRS (Coherus Biosciences)")
The difference between the consensus estimate and the actual stock price CHRS (Coherus Biosciences)
Coherus Biosciences is a biopharmaceutical company successfully transforming itself. Having started with biosimilars (analogs of expensive drugs), it is now launching its own innovative oncology drugs. This chart shows how much the current share price differs from the "fair" value predicted by analysts. It reflects their belief in this "turnaround."
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CHRS-Coherus-Biosciences&v=1772634890768 "A chart showing the difference between the consensus forecast and the actual stock price. CHRS (Coherus Biosciences)")
Analyst consensus forecast for stock prices by market segment - General oncology therapy
Coherus Biosciences is a biopharmaceutical company successfully transforming from a "biosimilar" (copy) player into an innovative oncology drug developer. This chart shows general expectations for the general oncology sector and reflects whether experts believe this complex transformation will be successful.
Analysts' consensus forecast for the overall market share price
Coherus Biosciences is a company specializing in "biosimilars." They produce "copies" of complex, expensive biologic drugs (such as cancer drugs or Humira), making them more accessible. This chart shows the overall market sentiment. For Coherus, operating in a "protective" (healthcare) but competitive (price wars) environment, these expectations impact budgets. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Coherus Biosciences
Coherus Biosciences is a pirate turned admiral. They started out as a biosimilar manufacturer (copies of expensive biologics like Humira) and now use that cash flow to fund their own R&D in immuno-oncology. This chart evaluates their transition, weighing their stable (but competitive) biosimilar business against the market's faith in their new R&D pipeline.
AKIMA Market Segment Index - General oncology therapy
Coherus Biosciences focuses on the development and commercialization of biosimilars (analogs of expensive biotech drugs) and also develops its own oncology drugs. This chart shows the average index for the oncology sector. It helps investors assess how Coherus's hybrid model (biosimilars and innovation) compares to the average.
The AKIM Index for the overall market
Coherus BioSciences is a biopharmaceutical company specializing in biosimilars (Udenyca) and innovative immuno-oncology (Loqtorzi). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this commercialization and competition story compares to overall economic trends.
